Goc Anna, Gehring Gebhard, Baltin Hartmut, Niedzwiecki Aleksandra, Rath Matthias
Department of Infectious Diseases, Dr. Rath Research Institute BV, 5941 Optical Ct, San Jose, CA 95138, USA.
Private Praxisklinik H. Baltin, Aschau/Chiemsee, Bavaria, Germany.
Ther Adv Chronic Dis. 2020 May 24;11:2040622320922005. doi: 10.1177/2040622320922005. eCollection 2020.
Lyme disease (LD) is a tick-borne infection caused by sensu lato. The current therapeutic approach to this disease is limited to antibiotics. However, after their administration, about 20% of patients experience delayed onset of this illness manifesting as lingering persistent symptoms.
To determine a suitable approach that would help reduce this number, we examined the efficacy of a composition of polyphenolic compounds (baicalein, luteolin, and rosmarinic acid) with fatty acids (monolaurin and cis-2-decenoic acid), and iodine/kelp in a Lyme disease animal model and volunteers.
The results showed that 4 weeks of dietary intake of this composition reduced the spirochete burden in animal tissues by about 75%. Basic and differential blood parameters did not show significant differences between control animals and the animals fed with this composition. Also, hepatic and renal toxicity markers were not changed and apoptosis was not observed. Relevant inflammatory cytokines such as IL-6, IL-17, TNF-α, and INF-γ, were elevated in infected animals but normalized in infected and treated animals. A small observational study revealed that after administration of this composition to 17 volunteers three times per day for 6 months, 67.4% of the volunteers with late or persistent LD, and not receptive to previous antibiotic application, responded positively, in terms of energy status as well as physical and psychological wellbeing to supplementation with this composition, while 17.7% had slight improvement, and 17.7% were none responsive.
We concluded that this specific composition revealed feasible benefits in late or persistent LD management, although double-blind controlled clinical trials are warranted.
莱姆病(LD)是一种由伯氏疏螺旋体狭义种引起的蜱传播感染。目前针对这种疾病的治疗方法仅限于使用抗生素。然而,在使用抗生素后,约20%的患者会出现疾病延迟发作,表现为持续存在的症状。
为了确定一种有助于减少这一比例的合适方法,我们在莱姆病动物模型和志愿者中研究了一种由多酚类化合物(黄芩素、木犀草素和迷迭香酸)与脂肪酸(月桂酸单甘油酯和顺-2-癸烯酸)以及碘/海带组成的组合物的疗效。
结果表明,在动物饮食中摄入该组合物4周可使动物组织中的螺旋体负荷降低约75%。对照动物与喂食该组合物的动物之间的基础血液参数和差异血液参数没有显著差异。此外,肝毒性和肾毒性标志物没有变化,也未观察到细胞凋亡。感染动物体内相关的炎性细胞因子如IL-6、IL-17、TNF-α和INF-γ升高,但在感染并接受治疗的动物中恢复正常。一项小型观察性研究显示,在17名志愿者中,每天三次给予该组合物,持续6个月后,67.4%患有晚期或持续性莱姆病且之前对抗生素治疗无反应的志愿者,在能量状态以及身体和心理健康方面对补充该组合物有积极反应,而17.7%有轻微改善,17.7%无反应。
我们得出结论,尽管需要进行双盲对照临床试验,但这种特定组合物在晚期或持续性莱姆病的管理中显示出可行的益处。